Novo Nordisk A/S vs Rockwell Automation — how do they compare? Novo Nordisk A/S trades at $38.33 (market cap $165.31B), while Rockwell Automation trades at $434.65 (market cap $48.21B). The key difference: Novo Nordisk A/S is far larger — about 3.4× Rockwell Automation's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Rockwell Automation for 74 Days on average.
| NVO | ROK | |
|---|---|---|
Market Cap | $165.31B | $48.21B |
Volume | 11,432,838 | 953,342 |
Sector | Health | Industrials |
52-Week High | $63.98 | $495.08 |
52-Week Low | $35.29 | $333.75 |
Typical Hold Time | 116 Days | 74 Days |
Enterprise Value | $179.56B | $51.34B |
Dividend Yield | 4.71% | 1.27% |
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
Rockwell Automation (ROK) trades at $439.01, down 0.65% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company maintains solid profitability with a 13.38% net income margin and 34.47% ROE, though valuation ratios like a P/E of 40.65 appear elevated. Recent news highlights leadership in industrial automation, including partnerships in AI cybersecurity and new robotic platforms, supporting positive sector momentum.
The outlook is cautiously optimistic, with a consensus price target of $489.89 implying ~12% upside, but high valuation and macroeconomic pressures pose risks. Earnings growth and automation demand are key catalysts, yet investors face volatility from competitive and economic headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →